NCT07110987View on ClinicalTrials.gov

The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in Treating Neonatal Indirect Hyperbilirubinemia

NARecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

March 1, 2027

Conditions
Hyperbilirubinemia, Neonatal Indirect
Interventions
PROCEDURE

Phototherapy

Triple continuous phototherapy per AAP Guudelines

DRUG

ursodeoxycholic acid (UDCA)

10mg/kg/day orally divided in two doses (URSORASHA) . Given with feeds untill the bilirubin level drop down to limits that don't need therapy due to AAP guidelines.

Trial Locations (1)

0000

RECRUITING

Lattakia University Hospital, Latakia

All Listed Sponsors
lead

Tishreen University Hospital

OTHER

NCT07110987 - The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in Treating Neonatal Indirect Hyperbilirubinemia | Biotech Hunter | Biotech Hunter